Skip to main content
OpenTrials
Completed

NCT Number: NCT03514511

Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis

The primary objective of this trial is to investigate the safety and tolerability of LEO 138559 in healthy subjects and subjects with moderate to severe atopic dermatitis.

The secondary objective of this trial is to study the pharmacokinetics and pharmacodynamics following administration of LEO 138559 to healthy subjects and subjects with moderate to severe atopic dermatitis.

Healthy subjects will be exposed to 7 different dose regimens of LEO 138559 (one dose regimen per subject).

Subjects with moderate to severe atopic dermatitis will be exposed to 2 different dose regimens of LEO 138559 (one dose regimen per subject).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Investigational site, Leeds, United Kingdom

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For healthy subjects and subjects with atopic dermatitis:

  • Males and females without childbearing potential.
  • Age between 18 and 55, inclusive.
  • Body mass index between 18 and 32 kg/m2, inclusive.
  • Healthy apart from atopic dermatitis for the subjects presenting the disease.

For subjects with atopic dermatitis only:

  • History of atopic dermatitis for more than 6 months.
  • Female subjects with childbearing potential and male subjects with female partners with childbearing potential using highly effective contraception from start of the trial and until a period after the last administered dose of trial drug.

Exclusion criteria

For healthy subjects and subjects with atopic dermatitis:

  • Any significant disease detected prior to enrolment.
  • Subjects who are still participating in a clinical trial or who have participated in a clinical trial within 3 months prior to enrolment or within 5 times of the half-life of the experimental therapy, whichever is longer.
  • Skin diseases that may interfere with the diagnosis of atopic dermatitis or assessment of the treatment.
  • Use of tanning beds or phototherapy within 6 weeks prior to enrolment.
  • Subjects with atopic dermatitis requiring more than 3 bleach baths from 4 weeks prior to screening until end of trial.
  • Blood pressure or pulse rate outside of the normal range.

For subjects with atopic dermatitis only:

  • Initiation of treatment of atopic dermatitis with prescription emollients during the screening period.

Treatment and study plan

LEO 138559

Drug

LEO 138559 is a compound in development at LEO Pharma A/S

LEO 138559 Placebo

Drug

LEO 138559 placebo

Primary outcomes

  1. Safety of LEO 138559 - numbers of subjects with adverse events

    Time frame: Day 1 to Day 120

  2. Safety of LEO 138559 - number of adverse events

    Time frame: Day 1 to Day 120

  3. Tolerability of LEO 138559 - number of local site reactions

    Time frame: Day 1 to Day 120

Sponsors and collaborators

Lead sponsor

LEO Pharma

Industry

Registry information

Official study title

Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEO 138559 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
May 2, 2018
Registry last updated
Feb 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.